2
Investors
About
Combotope Therapeutics develops tumor-specific antibodies targeting cancer-associated Tn/STn glycoepitopes using their proprietary SMART-Phage™ antibody discovery platform to generate therapeutic candidates for various modalities including ADCs, bispecifics, CAR-T, and radiolabeled therapies.
Explore Combotope Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.